Literature DB >> 20160413

Role of peroxisome proliferator-activated receptor-alpha in hepatobiliary injury induced by ammonium perfluorooctanoate in mouse liver.

Mutsuko Minata1, Kouji H Harada, Anna Kärrman, Toshiaki Hitomi, Michi Hirosawa, Mariko Murata, Frank J Gonzalez, Akio Koizumi.   

Abstract

Peroxisome proliferator-activated receptor-alpha (PPARalpha) has been suggested to protect against chemically induced hepatobiliary injuries in rodents. This function could mask the potential toxicities of perfluorooctanoic acid (PFOA) that is an emerging environmental contaminant and a weak ligand of PPARalpha. However its function has not been clarified. In this study, PFOA was found to elicit hepatocyte and bile duct injuries in Pparalpha-null mice after 4 wk treatment with PFOA ammonium salt (0, 12.5, 25, 50 micromol/kg/d, gavage). In wild-type mice, PFOA caused major hepatocellular damage dose-dependently and minor cholangiopathy observed only at 25 and 50 micromol/kg. In treated Pparalpha-null mice, PFOA produced marked fat accumulation, severe cholangiopathy, hepatocellular damage and apoptotic cells especially in bile ducts. Oxidative stress was also increased 4-fold at 50 micromol/kg and TNF-alpha mRNA was upregulated more than 3-fold at 25 micromol/kg in Pparalpha-null mice. Biliary bile acid/phospholipid ratios were higher in Pparalpha-null mice than in wild-type mice. Results from these studies suggest that PPARalpha is protective against PFOA and have a critical role in drug induced hepatobiliary injury.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20160413      PMCID: PMC7385711          DOI: 10.2486/indhealth.48.96

Source DB:  PubMed          Journal:  Ind Health        ISSN: 0019-8366            Impact factor:   2.179


  33 in total

1.  The rat canalicular conjugate export pump (Mrp2) is down-regulated in intrahepatic and obstructive cholestasis.

Authors:  M Trauner; M Arrese; C J Soroka; M Ananthanarayanan; T A Koeppel; S F Schlosser; F J Suchy; D Keppler; J L Boyer
Journal:  Gastroenterology       Date:  1997-07       Impact factor: 22.682

2.  High sensitivity of fatty liver Shionogi (FLS) mice to diethylnitrosamine hepatocarcinogenesis: comparison to C3H and C57 mice.

Authors:  Shuji Iwai; Takashi Murai; Susumu Makino; Wei Min; Keiichirou Morimura; Satoru Mori; Atsushi Hagihara; Shuichi Seki; Shoji Fukushima
Journal:  Cancer Lett       Date:  2006-03-29       Impact factor: 8.679

3.  Quantitative gas chromatographic determination of perfluorooctanoic acid as the benzyl ester in plasma and urine.

Authors:  M Ylinen; H Hanhijärvi; P Peura; O Rämö
Journal:  Arch Environ Contam Toxicol       Date:  1985-11       Impact factor: 2.804

Review 4.  Bile acid transporters: structure, function, regulation and pathophysiological implications.

Authors:  Waddah A Alrefai; Ravinder K Gill
Journal:  Pharm Res       Date:  2007-04-03       Impact factor: 4.200

5.  CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice.

Authors:  Martin Wagner; Emina Halilbasic; Hanns-Ulrich Marschall; Gernot Zollner; Peter Fickert; Cord Langner; Kurt Zatloukal; Helmut Denk; Michael Trauner
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

6.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors.

Authors:  T T Lu; M Makishima; J J Repa; K Schoonjans; T A Kerr; J Auwerx; D J Mangelsdorf
Journal:  Mol Cell       Date:  2000-09       Impact factor: 17.970

7.  Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia.

Authors:  Georgy Hartmann; Annie K Y Cheung; Micheline Piquette-Miller
Journal:  J Pharmacol Exp Ther       Date:  2002-10       Impact factor: 4.030

8.  Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.

Authors:  Peter Fickert; Andrea Fuchsbichler; Martin Wagner; Gernot Zollner; Arthur Kaser; Herbert Tilg; Robert Krause; Frank Lammert; Cord Langner; Kurt Zatloukal; Hanns-Ulrich Marschall; Helmut Denk; Michael Trauner
Journal:  Gastroenterology       Date:  2004-07       Impact factor: 22.682

9.  Comparative hepatic effects of perfluorooctanoic acid and WY 14,643 in PPAR-alpha knockout and wild-type mice.

Authors:  Douglas C Wolf; Tanya Moore; Barbara D Abbott; Mitchell B Rosen; Kaberi P Das; Robert D Zehr; Andrew B Lindstrom; Mark J Strynar; Christopher Lau
Journal:  Toxicol Pathol       Date:  2008-05-08       Impact factor: 1.902

10.  Improvements in epoxy resin embedding methods.

Authors:  J H LUFT
Journal:  J Biophys Biochem Cytol       Date:  1961-02
View more
  8 in total

1.  Perfluorooctanoic Acid (PFOA)-induced Liver Lesions in Two Strains of Mice Following Developmental Exposures: PPARα Is Not Required.

Authors:  Adam J Filgo; Erin M Quist; Mark J Hoenerhoff; Amy E Brix; Grace E Kissling; Suzanne E Fenton
Journal:  Toxicol Pathol       Date:  2014-11-14       Impact factor: 1.902

2.  Perfluorooctanoic acid activates multiple nuclear receptor pathways and skews expression of genes regulating cholesterol homeostasis in liver of humanized PPARα mice fed an American diet.

Authors:  J J Schlezinger; H Puckett; J Oliver; G Nielsen; W Heiger-Bernays; T F Webster
Journal:  Toxicol Appl Pharmacol       Date:  2020-08-19       Impact factor: 4.219

3.  Celecoxib attenuates hepatosteatosis by impairing de novo lipogenesis via Akt-dependent lipogenic pathway.

Authors:  Cong Zhang; Yuzhen Lu; Yingying Song; Liang Chen; Junjie Hu; Yan Meng; Xin Chen; Shan Li; Guohua Zheng; Zhenpeng Qiu
Journal:  J Cell Mol Med       Date:  2022-06-17       Impact factor: 5.295

4.  Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA).

Authors:  Matteo Convertino; Timothy R Church; Geary W Olsen; Yang Liu; Eddie Doyle; Clifford R Elcombe; Anna L Barnett; Leslie M Samuel; Iain R MacPherson; Thomas R J Evans
Journal:  Toxicol Sci       Date:  2018-05-01       Impact factor: 4.849

5.  Impairment of bile acid metabolism by perfluorooctanoic acid (PFOA) and perfluorooctanesulfonic acid (PFOS) in human HepaRG hepatoma cells.

Authors:  Anne-Cathrin Behr; Anna Kwiatkowski; Marcus Ståhlman; Felix Florian Schmidt; Claudia Luckert; Albert Braeuning; Thorsten Buhrke
Journal:  Arch Toxicol       Date:  2020-04-06       Impact factor: 5.153

Review 6.  Exposure to per- and Polyfluoroalkyl Substances and Markers of Liver Injury: A Systematic Review and Meta-Analysis.

Authors:  Elizabeth Costello; Sarah Rock; Nikos Stratakis; Sandrah P Eckel; Douglas I Walker; Damaskini Valvi; Dora Cserbik; Todd Jenkins; Stavra A Xanthakos; Rohit Kohli; Stephanie Sisley; Vasilis Vasiliou; Michele A La Merrill; Hugo Rosen; David V Conti; Rob McConnell; Leda Chatzi
Journal:  Environ Health Perspect       Date:  2022-04-27       Impact factor: 9.031

7.  Perfluorooctanoic acid induces liver and serum dyslipidemia in humanized PPARα mice fed an American diet.

Authors:  J J Schlezinger; T Hyötyläinen; T Sinioja; C Boston; H Puckett; J Oliver; W Heiger-Bernays; T F Webster
Journal:  Toxicol Appl Pharmacol       Date:  2021-07-10       Impact factor: 4.460

8.  Involvement of oxidative stress and inflammation in liver injury caused by perfluorooctanoic acid exposure in mice.

Authors:  Bei Yang; Weiying Zou; Zhenzhen Hu; Fangming Liu; Ling Zhou; Shulong Yang; Haibin Kuang; Lei Wu; Jie Wei; Jinglei Wang; Ting Zou; Dalei Zhang
Journal:  Biomed Res Int       Date:  2014-03-02       Impact factor: 3.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.